• AstraZeneca’s Truqap won US FDA clearance with abiraterone, prednisone, ADT for PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive prostate cancer.
• CAPItello-281 data showed a 19% cut in radiographic progression or death risk; median rPFS 33.2 months vs 25.7 months.
• A companion diagnostic to detect PTEN deficiency in prostate adenocarcinoma also received FDA authorization.
• An EU filing for the Truqap combination is under regulatory review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief on June 12, 2026, and is solely responsible for the information contained therein.